Durvalumab in Combination with Olaparib in Patients with Relapsed SCLC: Results from a Phase II Study

Durvalumab in Combination with Olaparib in Patients with Relapsed SCLC: Results from a Phase II Study is a paper indexed in PICO Portal from OpenAlex.

How many citations does Durvalumab in Combination with Olaparib in Patients with Relapsed SCLC: Results from a Phase II Study have?

Durvalumab in Combination with Olaparib in Patients with Relapsed SCLC: Results from a Phase II Study has 183 citations in the OpenAlex counts PICO Portal stores.

When was Durvalumab in Combination with Olaparib in Patients with Relapsed SCLC: Results from a Phase II Study published?

Durvalumab in Combination with Olaparib in Patients with Relapsed SCLC: Results from a Phase II Study has 2019 year in the PICO Portal index.

What is the open-access status of Durvalumab in Combination with Olaparib in Patients with Relapsed SCLC: Results from a Phase II Study?

Durvalumab in Combination with Olaparib in Patients with Relapsed SCLC: Results from a Phase II Study has bronze oa status in the PICO Portal index.

What is the DOI of Durvalumab in Combination with Olaparib in Patients with Relapsed SCLC: Results from a Phase II Study?

The DOI for Durvalumab in Combination with Olaparib in Patients with Relapsed SCLC: Results from a Phase II Study is on the source record.

What is the PMID of Durvalumab in Combination with Olaparib in Patients with Relapsed SCLC: Results from a Phase II Study?

The PMID for Durvalumab in Combination with Olaparib in Patients with Relapsed SCLC: Results from a Phase II Study is on the source record.

What is the OpenAlex record for Durvalumab in Combination with Olaparib in Patients with Relapsed SCLC: Results from a Phase II Study?

The OpenAlex for Durvalumab in Combination with Olaparib in Patients with Relapsed SCLC: Results from a Phase II Study is on the source record.